Online inquiry

IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11075MR)

This product GTTS-WQ11075MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF1 gene. The antibody can be applied in Pigmented villonodular synovitis (PVNS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000757.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1435
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11075MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5933MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ12326MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ11737MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ10732MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ3966MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ6102MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ14013MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ176MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1-26/3-67
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW